Nordea Investment Management AB Sells 46,241 Shares of COPT Defense Properties $CDP

Nordea Investment Management AB decreased its position in shares of COPT Defense Properties (NYSE:CDP) by 11.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 346,876 shares of the company’s stock after selling 46,241 shares during the period. Nordea Investment Management AB’s holdings in COPT Defense Properties were worth $9,660,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Allianz Asset Management GmbH increased its holdings in COPT Defense Properties by 31.9% during the 3rd quarter. Allianz Asset Management GmbH now owns 461,797 shares of the company’s stock valued at $13,420,000 after purchasing an additional 111,696 shares in the last quarter. Channing Capital Management LLC boosted its stake in COPT Defense Properties by 21.0% in the third quarter. Channing Capital Management LLC now owns 2,913,596 shares of the company’s stock worth $84,669,000 after purchasing an additional 506,593 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of COPT Defense Properties during the third quarter worth $1,203,000. JPMorgan Chase & Co. increased its stake in shares of COPT Defense Properties by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 3,566,073 shares of the company’s stock valued at $103,630,000 after buying an additional 253,558 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its holdings in shares of COPT Defense Properties by 83,723.7% in the third quarter. Picton Mahoney Asset Management now owns 31,853 shares of the company’s stock valued at $924,000 after buying an additional 31,815 shares during the last quarter.

COPT Defense Properties Trading Down 0.2%

Shares of CDP opened at $31.43 on Thursday. The stock’s fifty day simple moving average is $31.52 and its 200-day simple moving average is $29.93. The firm has a market capitalization of $3.56 billion, a PE ratio of 23.28 and a beta of 0.86. COPT Defense Properties has a 12-month low of $23.92 and a 12-month high of $32.82. The company has a quick ratio of 3.95, a current ratio of 3.95 and a debt-to-equity ratio of 1.77.

COPT Defense Properties (NYSE:CDP) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The firm had revenue of $197.36 million during the quarter, compared to analyst estimates of $188.79 million. COPT Defense Properties had a return on equity of 9.82% and a net margin of 19.94%.The company’s revenue was up 7.6% on a year-over-year basis. During the same period last year, the company earned $0.65 earnings per share. COPT Defense Properties has set its FY 2026 guidance at 2.710-2.790 EPS and its Q1 2026 guidance at 0.670-0.690 EPS. As a group, research analysts predict that COPT Defense Properties will post 2.67 earnings per share for the current year.

COPT Defense Properties Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.32 per share. The ex-dividend date is Tuesday, March 31st. This represents a $1.28 annualized dividend and a dividend yield of 4.1%. This is a positive change from COPT Defense Properties’s previous quarterly dividend of $0.31. COPT Defense Properties’s dividend payout ratio is presently 90.37%.

Insider Buying and Selling at COPT Defense Properties

In related news, Director Philip L. Hawkins sold 5,536 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $32.71, for a total transaction of $181,082.56. Following the completion of the sale, the director directly owned 15,188 shares of the company’s stock, valued at $496,799.48. The trade was a 26.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.42% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CDP has been the topic of a number of research analyst reports. Jefferies Financial Group increased their price objective on shares of COPT Defense Properties from $33.00 to $34.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Evercore reaffirmed an “outperform” rating on shares of COPT Defense Properties in a research note on Friday, February 6th. Citigroup upped their target price on shares of COPT Defense Properties from $29.00 to $34.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 10th. Truist Financial increased their price target on shares of COPT Defense Properties from $31.00 to $33.00 and gave the company a “hold” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of COPT Defense Properties in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, COPT Defense Properties currently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

COPT Defense Properties Profile

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.